Sorafenib
A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy.
Year introduced: 2019 (2003)
PubMed search builder options
Subheadings:
Tree Number(s): D02.065.950.681.757, D02.455.426.559.389.703.757, D03.066.515.530.750, D03.383.725.547.530.750
MeSH Unique ID: D000077157
Registry Number: 9ZOQ3TZI87
Entry Terms:
- BAY 43-9006
- BAY 439006
- BAY 43 9006
- Sorafenib Tosylate
- 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
- Nexavar
- BAY 545-9085
- BAY 5459085
- BAY 545 9085
- BAY-545-9085
- BAY5459085
- Sorafenib N-Oxide
- Sorafenib N Oxide
- BAY-673472
- BAY 673472
Pharmacologic Action: